Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells

British Journal of Cancer

Volumn 91, Issue 9, 2004, Pages 1703-1710

  Journe, F ^a   Chaboteaux, C ^a   Dumon, J C ^a   Leclercq, G ^a   Laurent, G ^b   Body, J J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF MONS   (Belgium)

Author keywords

Antioestrogen; Bisphosphonate; Breast cancer cells; Clodronate; Oestrogen receptor

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CRYSTAL VIOLET; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; STEROID; TAMOXIFEN;

ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN IBEP 2; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECT; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE REPORTER GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; REPORTER GENE; STAINING; STEROID FREE MEDIUM;

ANTIMETABOLITES; BREAST NEOPLASMS; CELL DIVISION; CLODRONIC ACID; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 9144258469     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602181     Document Type: Article

References (51)

1. Bardon S, Vignon F, Derocq D, Rochefort H (1984) The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the oestrogen receptor. Mol Cell Endocrinol 35: 89-96
2. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139
3. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Caroti C, Farris A, Cruciani G, Villa E, Schieppati G, Mustacchi G (2001) Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 19: 4209-4215
4. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16: 3890-3899
5. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748-3757
6. Brodie AM, Njar VC (2000) Aromatase inhibitors and their application in breast cancer treatment. Steroids 65: 171-179
7. Busch M, Rave-Frank M, Hille A, Duhmke E (1998) Influence of clodronate on breast cancer cells in vitro. Eur J Med Res 3: 427-431
8. Coleman RE (2003) Current and future status of adjuvant therapy for breast cancer. Cancer 97: 880-886
9. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077-2082
10. Demirpence E, Duchesne MJ, Badia E, Gagne D, Pons M (1993) MVLN cells: a bioluminescent MCE-7-derived cell line to study the modulation of estrogenic activity. J Steroid Biochem Mol Biol 46: 355-364
11. Devleeschouwer N, Legros N, Olea-Serrano N, Paridaens R, Leclercq G (1987) Estrogen conjugates and serum factors mediating the oestrogenic trophic effect on MCF-7 cell growth. Cancer Res 47: 5883-5887
12. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363
13. Daggers PH, Segars JH (2002) Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in oestrogen signaling. Trends Endocrinol Metab 13: 422-427
14. Fleisch H (2003) Bisphosphonates in osteoporosis. Eur Spine J 12(Suppl 2): S142-S146
15. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358- 1367
16. Fromigue O, Lagneaux L, Body JJ (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221
17. Goss PE, Strasser K (2001) Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19: 881-894
18. Harper-Wynne C, Dowsett M (2001) Recent advances in the clinical application of aromatase inhibitors. J Steroid Biochem Mol Biol 76: 179-186
19. Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, A'Hern R, Dowsett M (2002) Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11: 614-621
20. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton III LJ, Riggs BL (2002) Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 17: 172-178
21. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP (1999) Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci USA 96: 4686-4691
22. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134
23. Jensen J, Kitlen JW, Briand P, Labrie F, Lykkesfeldt AE (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol 84: 469-478
24. Journe F, Body JJ, Leclercq G, Nonclercq D, Laurent G (2004a) Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma. Breast Cancer Res Treat 86: 39-53
25. Journe F, Chaboteaux C, Laurent G, Dumon JC, Body JJ (2004b) Ibandronate inhibits the proliferation of estrogen receptor-positive breast cancer cells: evidence for additivity with antiestrogens. Bone 34(Suppl 1): S59, abstract #23
26. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74: 311-317
27. Lee MV, Fong EM, Singer FR, Guenette RS (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608
28. Lin JH, Chen IW, Duggan DE (1992) Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20: 473-478
29. Lipton A (2003) Bisphosphonates and metastatic breast carcinoma. Cancer 97: 848-853
30. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ (1994) Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154: 2585-2588
31. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589
32. Miller WR, Dixon JM, Cameron DA, Anderson TJ (2001) Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 79: 103-107
33. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
34. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T (1997) Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 20: 399-404
35. Myatt L, Cukier D, Elder MG, White JO (1985) Activation of estrogen receptor complexes: evidence for the distinct regulation of ligand and oligonucleotide binding sites. Biochim Biophys Acta 845: 304-310
36. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767
37. Neville-Webbe HL, Holen I, Coleman RE (2002) The anti-tumour activity of bisphosphonates. Cancer Treat Rev 28: 305-319
38. Osterman T, Lauren L (1991) Level of clodronate in bone after single and repeated subcutaneous injections in rats. Pharmacol Toxicol 69: 369-371
39. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 1363-1374
40. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219-3224
41. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78-84
42. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106
43. Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19: 10-17
44. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105
45. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA (1996) Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci USA 93: 3068-3073
46. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468
47. Siwek B, Larsimont D, Lacroix M, Body JJ (1998) Establishment and characterization of three new breast-cancer cell lines. Int J Cancer 76: 677-683
48. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348: 2431-2442
49. Villikka K, Perttunen K, Rosnell J, Ikavalko H, Vaho H, Pylkkanen L (2002) The absolute bioavailability of clodronate from two different oral doses. Bone 31: 418-421
50. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88: 2979-2988
51. Zhao Z, Tan Z, Diltz CD, You M, Fischer EH (1996) Activation of mitogen-activated protein (MAP) kinase pathway by pervanadate, a potent inhibitor of tyrosine phosphatases. J Biol Chem 271: 22251-22255